skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Low-Dose Radiotherapy in Indolent Lymphoma

Abstract

Purpose: To assess the response rate, duration of response, and overall survival after low-dose involved-field radiotherapy in patients with recurrent low-grade lymphoma or chronic lymphocytic leukemia (CLL). Methods and Materials: Forty-three (24 women, 19 men) consecutive patients with indolent lymphoma or CLL were treated with a total dose of 4 Gy (2 x 2 Gy) using 6- 18-MV photons. The median age was 73 years (range, 39-88). Radiotherapy was given either after (n = 32; 75%) or before (n = 11; 25%) chemotherapy. The median time from diagnosis was 48 months (range, 1-249). The median follow-up period was 20 months (range, 1-56). Results: The overall response rate was 90%. Twelve patients (28%) had a complete response, 15 (35%) had a partial response, 11 (26%) had stable disease, and 5 (11%) had progressive disease. The median overall survival for patients with a positive response (complete response/partial response/stable disease) was 41 months; for patients with progressive disease it was 6 months (p = 0.001). The median time to in-field progression was 21 months (range, 0-24), and the median time to out-field progression was 8 months (range, 0-40). The 3-year in-field control was 92% in patients with complete response (median was not reached).more » The median time to in-field progression was 9 months (range, 0.5-24) in patients with partial response and 6 months (range, 0.6-6) in those with stable disease (p < 0.05). Younger age, positive response to radiotherapy, and no previous chemotherapy were the best factors influencing the outcome. Conclusions: Low-dose involved-field radiotherapy is an effective treatment in the management of patients with recurrent low-grade lymphoma or CLL.« less

Authors:
 [1]; ;  [2];  [1];  [2];  [1]
  1. Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne (Switzerland)
  2. Department of Radiation Oncology, University Hospital of Geneva (Switzerland)
Publication Date:
OSTI Identifier:
21590412
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 81; Journal Issue: 3; Other Information: DOI: 10.1016/j.ijrobp.2010.12.062; PII: S0360-3016(11)00066-6; Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CHEMOTHERAPY; DIAGNOSIS; LEUKEMIA; LYMPHOMAS; PHOTONS; RADIATION DOSES; RADIOTHERAPY; BOSONS; DISEASES; DOSES; ELEMENTARY PARTICLES; IMMUNE SYSTEM DISEASES; MASSLESS PARTICLES; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; RADIOLOGY; THERAPY

Citation Formats

Rossier, Christine, Schick, Ulrike, Miralbell, Raymond, Mirimanoff, Rene O., Weber, Damien C., and Ozsahin, Mahmut, E-mail: Esat-Mahmut.Ozsahin@chuv.ch. Low-Dose Radiotherapy in Indolent Lymphoma. United States: N. p., 2011. Web. doi:10.1016/j.ijrobp.2010.12.062.
Rossier, Christine, Schick, Ulrike, Miralbell, Raymond, Mirimanoff, Rene O., Weber, Damien C., & Ozsahin, Mahmut, E-mail: Esat-Mahmut.Ozsahin@chuv.ch. Low-Dose Radiotherapy in Indolent Lymphoma. United States. doi:10.1016/j.ijrobp.2010.12.062.
Rossier, Christine, Schick, Ulrike, Miralbell, Raymond, Mirimanoff, Rene O., Weber, Damien C., and Ozsahin, Mahmut, E-mail: Esat-Mahmut.Ozsahin@chuv.ch. Tue . "Low-Dose Radiotherapy in Indolent Lymphoma". United States. doi:10.1016/j.ijrobp.2010.12.062.
@article{osti_21590412,
title = {Low-Dose Radiotherapy in Indolent Lymphoma},
author = {Rossier, Christine and Schick, Ulrike and Miralbell, Raymond and Mirimanoff, Rene O. and Weber, Damien C. and Ozsahin, Mahmut, E-mail: Esat-Mahmut.Ozsahin@chuv.ch},
abstractNote = {Purpose: To assess the response rate, duration of response, and overall survival after low-dose involved-field radiotherapy in patients with recurrent low-grade lymphoma or chronic lymphocytic leukemia (CLL). Methods and Materials: Forty-three (24 women, 19 men) consecutive patients with indolent lymphoma or CLL were treated with a total dose of 4 Gy (2 x 2 Gy) using 6- 18-MV photons. The median age was 73 years (range, 39-88). Radiotherapy was given either after (n = 32; 75%) or before (n = 11; 25%) chemotherapy. The median time from diagnosis was 48 months (range, 1-249). The median follow-up period was 20 months (range, 1-56). Results: The overall response rate was 90%. Twelve patients (28%) had a complete response, 15 (35%) had a partial response, 11 (26%) had stable disease, and 5 (11%) had progressive disease. The median overall survival for patients with a positive response (complete response/partial response/stable disease) was 41 months; for patients with progressive disease it was 6 months (p = 0.001). The median time to in-field progression was 21 months (range, 0-24), and the median time to out-field progression was 8 months (range, 0-40). The 3-year in-field control was 92% in patients with complete response (median was not reached). The median time to in-field progression was 9 months (range, 0.5-24) in patients with partial response and 6 months (range, 0.6-6) in those with stable disease (p < 0.05). Younger age, positive response to radiotherapy, and no previous chemotherapy were the best factors influencing the outcome. Conclusions: Low-dose involved-field radiotherapy is an effective treatment in the management of patients with recurrent low-grade lymphoma or CLL.},
doi = {10.1016/j.ijrobp.2010.12.062},
journal = {International Journal of Radiation Oncology, Biology and Physics},
number = 3,
volume = 81,
place = {United States},
year = {Tue Nov 01 00:00:00 EDT 2011},
month = {Tue Nov 01 00:00:00 EDT 2011}
}